Holen Sie sich die Stockscreener-App
3.48
6.45%
-0.24
Vorhandelsmarkt:
3.48
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Why Quince Therapeutics Inc. stock is considered a top pick2025 Technical Overview & Reliable Volume Spike Trade Alerts - DonanımHaber
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital - Yahoo Finance
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - BioSpace
D. Boral Capital Maintains Quince Therapeutics (QNCX) Buy Recommendation - Nasdaq
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus
Quince Therapeutics (NASDAQ:QNCX) Price Target Raised to $5.00 at D. Boral Capital - MarketBeat
Quince marks final patient visit in NEAT phase 3 study - marketscreener.com
Quince Marks Final Patient Visit in NEAT Phase 3 Study - TradingView — Track All Markets
Quince Therapeutics (QNCX) Concludes Phase 3 Trial for Key Drug - GuruFocus
Quince Therapeutics (QNCX) CEO moves 739,885 common shares to Thye Trust - Stock Titan
Citizens reiterates Market Outperform rating on Quince Therapeutics stock By Investing.com - Investing.com Canada
Quince Therapeutics publishes early-stage data on eDSP drug delivery system - Investing.com Nigeria
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - BioSpace
Citizens reiterates Market Outperform rating on Quince Therapeutics stock - Investing.com India
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonar - pharmiweb.com
Quince Therapeutics (QNCX) Publishes Promising Early Clinical Study Results - GuruFocus
Check out these key findings about Quince Therapeutics Inc (QNCX) - setenews.com
COO Hannah Acquires 27,551 Of Quince Therapeutics Inc [QNCX] - TradingView — Track All Markets
Trading Action: Is Quince Therapeutics Inc stock a safe buy before earnings2025 Price Momentum & Accurate Trade Setup Notifications - moha.gov.vn
Quince Therapeutics, Inc. (QNCX) -11.5% in After-hours: No Clear Catalyst Driving Decline - Stocks Telegraph
Quince Therapeutics, Inc. (QNCX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why Quince Therapeutics Inc. stock is trending among retail traders2025 Performance Recap & Real-Time Buy Signal Alerts - Newser
Why Quince Therapeutics Inc. stock remains resilientWeekly Investment Recap & Weekly Top Stock Performers List - Newser
Quince Therapeutics (QNCX) Stock Analysis Report | Financials & Insights - Benzinga
Prepare Yourself for Liftoff: Quince Therapeutics Inc (QNCX) - Setenews
Quince Therapeutics Stock Surges 105%, With A 8-Day Winning Spree - Trefis
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Consensus Target Price from Analysts - Defense World
Quince Therapeutics, Inc. (QNCX) 18.8% in Intraday Trading: Surge Amid Upcoming Investor Events - Stocks Telegraph
Quince Therapeutics Stock Rockets 59% With 7-Day Winning Streak - Trefis
Quince Therapeutics: Could NEAT Phase 3 Data Deliver The First Therapy For Ataxia-Telangiectasia? - RTTNews
Adversity is less terrifying than hope: Quince Therapeutics Inc (QNCX) - Setenews
EBITDA per share of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics to Participate at Investor Events in December 2025 - Markets Financial Content
Quince Therapeutics (QNCX) joins investor events as Phase 3 NEAT data in 2026 - Stock Titan
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Quince Therapeutics Inc. stock a dividend growth opportunity2025 Historical Comparison & Growth Oriented Trade Recommendations - newser.com
A new trading data show Quince Therapeutics Inc (QNCX) is showing positive returns. - setenews.com
Can Quince Therapeutics Inc. stock weather global recessionWeekly Stock Recap & Detailed Earnings Play Alerts - newser.com
Sentiment analysis tools applied to Quince Therapeutics Inc.Quarterly Portfolio Report & Weekly High Conviction Ideas - newser.com
How analysts rate Quince Therapeutics Inc. stock todayM&A Rumor & Low Risk Entry Point Tips - newser.com
Statistical indicators supporting Quince Therapeutics Inc.’s strengthGDP Growth & Technical Entry and Exit Alerts - newser.com
Can Quince Therapeutics Inc. stock double in next 5 yearsMarket Trend Review & Weekly Hot Stock Watchlists - newser.com
Combining machine learning predictions for Quince Therapeutics Inc.Global Markets & Daily Chart Pattern Signal Reports - newser.com
Is Quince Therapeutics Inc. stock a good choice for value investorsMarket Risk Summary & Risk Managed Investment Strategies - newser.com
How interest rate cuts could boost Quince Therapeutics Inc. stockShort Setup & Daily Oversold Stock Bounce Ideas - newser.com
What indicators show strength in Quince Therapeutics Inc.July 2025 Levels & Weekly High Return Opportunities - newser.com
0.31%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):